Journal
HUMAN VACCINES & IMMUNOTHERAPEUTICS
Volume 9, Issue 1, Pages 122-124Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/hv.22317
Keywords
live attenuated; pandemic H1N1 vaccine; post-marketing surveillance
Categories
Funding
- Serum Institute of India Ltd
Ask authors/readers for more resources
A live attenuated pandemic H1N1 influenza vaccine was developed in India. A post marketing surveillance was conducted retrospectively in healthy individuals (>= 3 y) who were vaccinated intranasally around one year before. After consent, the subjects recorded adverse events developing within 42 d. Among 7,565 individuals (3-85 y), a total of 81 solicited adverse reactions (1%) were reported in 49 subjects (0.65%). The reactions included mild to moderate respiratory symptoms. No H1N1 case was encountered during one year post vaccination. The data show the safety of the live attenuated influenza vaccine platform developed in India.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available